Wassim Kassouf
- Professor of Urology
- Stephen Jarislowsky Chair in Urology
MD, CM, FRCSC
Clinical practice focuses on all aspects of urologic oncology (including bladder, prostate, renal, testes, and penile cance
Oncology (including bladder, prostate, renal, testes, and penile cancer
Biology and Therapy for Bladder Cancer
Molecular Markers for Bladder Cancer听
Patterns of practice and outcomes in urologic oncology
1.Marcq G, Cury F, Brimo F, Kassouf W. Impact of Programmed Death-ligand 1 Expression on Outcomes in Patients with bladder cancer Treated with radiation. Eur Urol Open Sci. 2022
2.Shinde-Jadhav S, Mansure JJ, Rayes RF, Marcq G, Ayoub M, Skowronski R, Kool R, Bourdeau F, Brimo F, Spicer J, Kassouf W. Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer. Nat Commun. 2021 May 13;12(1):2776. doi: 10.1038/s41467-021-23086-z.PMID: 33986291
3.Tholomier C, Marcq G, Shinde-Shadhav S, Ayoub M, Huang JM, Kool R, Skowronski R, Brimo F, Mansure JJ, and Kassouf W. Optimizing sequence of PD-L1 immune-checkpoint inhibitors and radiation therapy in bladder cancer. Bladder Cancer 6:295-302, 2020.
4.Marcq G, Souhami L, Cury FL, Salimi A, Aprikian A, Tanguay S, Vanhuyse M, Rajan R, Brimo F, Mansure JJ, Kassouf W. Phase I Trial of Atezolizumab plus Trimodal Therapy in Patients with localized Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2021 Jan 6:S0360-3016(20)34729-5. doi: 10.1016/j.ijrobp.2020.12.033
5.Rompr茅-Brodeur A. Ayoub M, Shinde-Jadhav S, Piccirillo C, Seuntjens J, Fadi Brimo F, Mansure J, Kassouf W. PD-1/PD-L1 Immune-Checkpoint Inhibition with Radiation in Bladder Cancer: In Situ and Abscopal Effects. Mol Cancer Ther, 2020 19(1):211-22, doi: 10.1158/1535-7163.MCT-18-0986
6.Ayoub M, Shinde-Jadhav S, Mansure JJ, Alvarez F, Connell T, Seuntjens J, Piccirillo CA, Kassouf W. The immune mediated role of extracellular HMGB1 in a heterotopic model of bladder cancer radioresistance. Sci Rep. 2019 Apr 23;9(1):6348. doi: 10.1038/s41598-019-42864-w.
7.Yu A, Mansure JJ, Solanki S, Siemens DR, Koti M, Dias ABT, Burnier MM, Brimo F, Kassouf W. Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. PLoS One. 2018 Oct 11;13(10):e0205746. doi: 10.1371/journal.pone.0205746. eCollection 2018.
8.Bachir B, Souhami L, Mansure JJ, Brimo F, Vanhuyse M, Sturgeon J, Cury F, Aprikian A, Tanguay S, and Kassouf W. Phase I clinical trial of everolimus combined with trimodality therapy in patients with muscle invasive bladder cancer. Bladder Cancer. 2017, 27:105-12.
9. Shrivastava S, Mansure JJ, Almajed W, Cury F, Ferbeyre G, Popovic M, Seuntjens J, Kassouf W. Role of HMGB1 in radio-resistance of bladder cancer. Mol Cancer Ther, 15(3):471-9, 2016.
10. Kamat AM, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W, Guo C, and Kassouf W. Bladder cancer. Lancet, 2016 Dec 3;388(10061):2796-2810
听
